LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: From discovery to clinical proof of concept
Tamer Coşkun, Shweta Urva, William C. Roell, Hongchang Qu, Corina Loghin, Julie S. Moyers, Libbey S. O’Farrell, Daniel A. Briere, Kyle W. Sloop, Melissa K. Thomas, Valentina Pirro, David B. Wainscott, Francis S. Willard, Matthew Abernathy, LaRonda L. Morford, Yu Du, Charles Benson, Ruth E. Gimeno, Axel Haupt, Zvonko Miličević
Topics & Concepts
Glucagon receptorWeight lossGlycemicAgonistEndocrinologyInternal medicineGlucagon-like peptide-1MedicineTolerabilityReceptorGlucagon-like peptide 1 receptorDiabetes mellitusGlucagonType 2 diabetesObesityInsulinAdverse effectDiabetes Treatment and ManagementPharmacology and Obesity TreatmentMetabolism, Diabetes, and Cancer